Owl Therapeutics ("Owl"), a biopharmaceutical company developing drugs to supercharge microglia, the immune cells of the ...

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

Scientists have created a new atlas of plant cells during immune response, in turn discovering a new rare cell state, called Primary IMmunE Responder (PRIMER), that acts as an immune response hub to ...

IGM Biosciences has decided to halt development of imvotamab and IGM-2644, two IgM-based bispecific antibody T cell engagers for autoimmune diseases, and cut its staff by 73%. The biotechnology ...

IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with autoimmune and inflammatory diseases, today announced a strategic ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Fred Hutch grew from a regional cancer center into a world-class biomedical research and clinical care institution known for ...

There is an undeniable connection between a strong immune system and nutrition. Learn why what you eat matters and other ways ...

Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Eliem Therapeutics is continuing its transformation into an immune-mediated disease company by paying $9 million to ...

Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...